Skip to main content
. 2020 Jun 9;3(3):e00158. doi: 10.1002/edm2.158

FIGURE 1.

FIGURE 1

Percentage of the initial cohort of patients with remission and persistent disease following first‐line treatment of acromegaly with trans‐sphenoidal surgery (TSS); and second‐line therapy with somatostatin analogue (SSA) therapy. *Assuming efficacy of SSA therapy of 40% in achieving target GH < 2.5 mg/L and normal age‐related IGF‐I